Citigroup Inc Applied Therapeutics Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Applied Therapeutics Inc. stock. As of the latest transaction made, Citigroup Inc holds 69,667 shares of APLT stock, worth $61,306. This represents 0.0% of its overall portfolio holdings.

Number of Shares

69,667

Previous 21,179 228.94%

Holding current value

$61,306

Previous $98,000 504.08%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$4.35 - $8.5 $210,922 - $412,148	48,488 Added 228.94%	69,667 $592,000
Q2 2024 Aug 12, 2024	SELL	$4.04 - $6.37 $394,405 - $621,871	-97,625 Reduced 82.17%	21,179 $98,000
Q1 2024 May 10, 2024	SELL	$2.25 - $7.4 $227,524 - $748,302	-101,122 Reduced 45.98%	118,804 $807,000
Q4 2023 Feb 09, 2024	BUY	$1.84 - $3.35 $283,268 - $515,732	153,950 Added 233.34%	219,926 $736,000
Q3 2023 Nov 09, 2023	BUY	$1.26 - $2.77 $83,129 - $182,753	65,976 New	65,976 $164,000
Q1 2023 May 11, 2023	BUY	$0.75 - $1.21 $264,633 - $426,942	352,845 Added 120424.91%	353,138 $286,000
Q4 2022 Feb 09, 2023	SELL	$0.54 - $1.12 $54,892 - $113,850	-101,652 Reduced 99.71%	293 $0
Q3 2022 Nov 10, 2022	BUY	$0.86 - $1.55 $79,866 - $143,945	92,868 Added 1023.11%	101,945 $95,000
Q2 2022 Aug 10, 2022	BUY	$0.76 - $2.64 $4,769 - $16,568	6,276 Added 224.06%	9,077 $9,000
Q1 2022 May 12, 2022	SELL	$1.48 - $6.22 $3,998 - $16,806	-2,702 Reduced 49.1%	2,801 $6,000
Q4 2021 Feb 10, 2022	BUY	$8.77 - $18.29 $15,970 - $33,306	1,821 Added 49.46%	5,503 $49,000
Q3 2021 Nov 10, 2021	BUY	$13.54 - $22.06 $49,854 - $81,224	3,682 New	3,682 $61,000

Others Institutions Holding APLT

# of Institutions

140

Shares Held

112M

Call Options Held

1.68M

Put Options Held

1.91M

View Full List

About Applied Therapeutics Inc.

Ticker APLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,700
Market Cap $42.3M
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...

More about APLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account